Effect of lyophilized recombinant human brain natriuretic peptide combined with bumetanide in the treatment of patients with acute left heart failure and its influences on clinical symptoms and cardiac function
Objective To investigate the effect of lyophilized recombinant human brain natriuretic peptide combined with bumetanide in the treatment of patients with acute left heart failure and its influences on clinical symptoms and cardiac function.Methods A total of 100 patients with acute left heart failure from September 2022 to September 2023 were selected as the research objects and divided into control group and observation group by random number table method,with 50 cases in each group.Both groups were given symptomatic treatment.On this basis,the control group was treated with bumetanide,and the observation group was treated with lyophilized recombinant human brain natriuretic peptide combined with bumetanide.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was significantly higher than that in the control group(P<0.05).The relief time of dyspnea in the observation group was shorter than that in the control group(P<0.05);after treatment,the respiratory rate and plasma N-terminal pro-brain natriuretic peptide level in the observation group were lower than those in the control group(P<0.05).After treatment,the left ventricular end-diastolic diameter and left ventricular end-systolic diameter in the observation group were less than those in the control group,and the left ventricular ejection fraction was higher than that in the control group(P<0.05).After treatment,the malondialdehyde(MDA)level,heart rate,systolic blood pressure and diastolic blood pressure in the observation group were lower than those in the control group,and the levels of superoxide dismutase(SOD)and glutathione peroxidase(GSH-Px)were higher than those in the control group(P<0.05).Conclusion The lyophilized recombinant human brain natriuretic peptide combined with bumetanide in the treatment of patients with acute left heart failure has a significant effect,which can relieve clinical symptoms,promote the improvement of cardiac function,and down-regulate the level of plasma N-terminal pro-brain natriuretic peptide.
lyophilized recombinant human brain natriuretic peptidebumetanideacute left heart failurecardiac function
维普
万方数据
